Adnexus continues to have genomic surveillance and monitoring of the virus epidemiology for new mutations.

Application of Sutra™ AI Platform to analyze the amino acid sequences of the targeted viruses to identify conserved, immutable, and neutralizable sites on the targeted viruses, bacteria and fungus. This assists in developing monoclonal Antibodies for the viruses and novel antibacterial and anti-fungal drugs.

As a part of this process, 3 Dimensional models of these conserved targets are generated, and the targets are analyzed for linearity, accessibility by antibodies, and neutralizability by antibodies. Adnexus’ scientists produce multiple broadly neutralizing antibodies targeting these multiple conserved, immutable epitopes on the targeted virus.

Adnexus is employing Artificial Intelligence for use in in-vitro diagnostic tests that diagnose viral diseases based on the presence of the conserved sites that remain unaffected by mutations. Adnexus has identified conserved targets for numerous infectious diseases for humans and animals. Documented studies show better clinical outcomes and delayed progression of diseases if patients have the antibodies to the conserved targets. We are also working on prognostic tests utilizing A.I. to predict the immune response before receiving viral therapy. This will allow physicians to understand if a patient favorably will respond to a particular antiviral treatment. Adnexus is also developing novel biomarkers for multiple infectious diseases, sepsis and neurogenerative disorders.

As we have learned from the current pandemic, most pandemics originate from animals and spillover events from animals to humans. An essential component of pandemic preparedness and prevention, one must recognize the link between the health of people, animals, and the environment, as well as the relevant disciplines and the communities within them.

In early drug discovery and development programs, increasing safety, efficacy, and probability of success.